Antifungal Activity of a Novel Triazole, Efinaconazole and Nine Comparators Against 354 Molecularly Identified Aspergillus Isolates Publisher Pubmed



Taheri Rizi Z^{1, 2} ; Abastabar M^{2, 3} ; Fakhim H^{4, 5} ; Ilkit M⁶ ; Ahangarkani F^{1, 3} ; Javidnia J^{1, 2} ; Haghani I^{2, 3} ; Meis JF^{7, 8} ; Badali H^{2, 3, 9} Show Affiliations
Source: Mycopathologia Published:2020

Abstract

Management of superficial aspergillosis is a major challenge owing to the frequent relapses and treatment failure, which may pose a potential risk, thereby gradually developing resistant species. Therefore, necessitating the development of new antifungals with higher potency should be considered as alternative strategies for efficient management of infections. We aimed to investigate the susceptibility of Aspergillus isolates toward a novel triazole, efinaconazole, in comparison with various classes of antifungal drugs. Antifungal susceptibility testing was performed according to the Clinical and Laboratory Standards Institute M38-A2 guidelines. Efinaconazole exhibited poor activity against mutant A. fumigatus strains, A. niger sensu stricto, and A. tubingensis with GM MIC values of 3.62, 1.62, and 2 μg/ml, respectively; however, surprisingly, it efficiently inhibited the growth of A. terreus sensu stricto, followed by wild-type A. fumigatus and A. flavus with GM MIC values of 0.29, 0.42, and 0.52 μg/ml, respectively. Presumably, efinaconazole is inefficient in aspergillosis treatment due to the low susceptibility of A. niger sensu stricto, A. tubingensis, and mutant A. fumigatus; however, it may be effective in treating superficial aspergillosis caused by wild-type A. fumigatus, A. terreus sensu stricto, and A. flavus. Further studies are needed to determine how these findings may translate into in vivo efficacy. © 2020, Springer Nature B.V.